SG11201704584RA - Thiotriazole compound and its use in parasitic protozoal infections - Google Patents

Thiotriazole compound and its use in parasitic protozoal infections

Info

Publication number
SG11201704584RA
SG11201704584RA SG11201704584RA SG11201704584RA SG11201704584RA SG 11201704584R A SG11201704584R A SG 11201704584RA SG 11201704584R A SG11201704584R A SG 11201704584RA SG 11201704584R A SG11201704584R A SG 11201704584RA SG 11201704584R A SG11201704584R A SG 11201704584RA
Authority
SG
Singapore
Prior art keywords
protozoal infections
parasitic protozoal
thiotriazole
compound
thiotriazole compound
Prior art date
Application number
SG11201704584RA
Inventor
Hernandez Beatriz Diaz
Velando Esther Pilar Fernandez
David Matthew Wilson
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of SG11201704584RA publication Critical patent/SG11201704584RA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/02Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06Antimalarials
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG11201704584RA 2014-12-22 2015-12-21 Thiotriazole compound and its use in parasitic protozoal infections SG11201704584RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14382555 2014-12-22
PCT/EP2015/080730 WO2016102431A1 (en) 2014-12-22 2015-12-21 Thiotriazole compound and its use in parasitic protozoal infections

Publications (1)

Publication Number Publication Date
SG11201704584RA true SG11201704584RA (en) 2017-07-28

Family

ID=52146396

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201704584RA SG11201704584RA (en) 2014-12-22 2015-12-21 Thiotriazole compound and its use in parasitic protozoal infections

Country Status (16)

Country Link
US (1) US20170368034A1 (en)
EP (1) EP3237400A1 (en)
JP (1) JP2017538776A (en)
KR (1) KR20170097051A (en)
CN (1) CN107108572A (en)
AR (1) AR103219A1 (en)
AU (1) AU2015371169A1 (en)
BR (1) BR112017013545A2 (en)
CA (1) CA2971668A1 (en)
PE (1) PE20171081A1 (en)
PH (1) PH12017501072A1 (en)
RU (1) RU2017126044A (en)
SG (1) SG11201704584RA (en)
TW (1) TW201636340A (en)
UY (1) UY36469A (en)
WO (1) WO2016102431A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210780A1 (en) * 2018-06-19 2021-04-21 Novartis Ag CYANOTRIAZOLE COMPOUNDS AND USES OF THEM
EP4075980A4 (en) * 2019-12-18 2023-10-11 Stinginn LLC Substituted 1,2, 4-triazoles and methods of use

Also Published As

Publication number Publication date
US20170368034A1 (en) 2017-12-28
WO2016102431A1 (en) 2016-06-30
UY36469A (en) 2016-06-30
TW201636340A (en) 2016-10-16
PE20171081A1 (en) 2017-08-03
RU2017126044A (en) 2019-01-24
AU2015371169A1 (en) 2017-06-29
CN107108572A (en) 2017-08-29
CA2971668A1 (en) 2016-06-30
PH12017501072A1 (en) 2017-11-27
EP3237400A1 (en) 2017-11-01
BR112017013545A2 (en) 2018-03-06
AR103219A1 (en) 2017-04-26
JP2017538776A (en) 2017-12-28
KR20170097051A (en) 2017-08-25

Similar Documents

Publication Publication Date Title
IL252216A0 (en) Difluoromethyl-aminopyridines and difluoromethyl-aminopyrimidines
HK1231471A1 (en) 6-heteroaryloxy- and 6-aryloxy-quinoline-2-carboxamides and uses thereof 6-- 6--2-
HK1244488A1 (en) Biguanide compound and use thereof
GB201413355D0 (en) Compositons and methods
HK1231376A1 (en) Topical formulations and uses thereof
HK1245461A1 (en) Improvements in counting devices
EP3127164A4 (en) P-tunneling field effect transistor device with pocket
HK1243077A1 (en) Piperidinylpyrazolopyrimidinones and their use
GB2514927B (en) Thiamethoxam and uses thereof
IL250729A0 (en) Pyrazolothiazole compound and medicine comprising same
SG11201704584RA (en) Thiotriazole compound and its use in parasitic protozoal infections
PL3129705T3 (en) Light-shaping device and arrangement
GB201404848D0 (en) Pathogenic infections
SG11201700191PA (en) Microbiocides and uses thereof
PT3160263T (en) Compositions and methods for preventing infections
GB201813934D0 (en) Thiamethoxam and uses thereof
GB2533105B (en) Solectron field effect transistor and inverter
PL3229772T3 (en) 6-aryl-9-glycosylpurines and use thereof
GB201421709D0 (en) Ranging and positioning system
GB201404728D0 (en) Disc-over incorporating disc-heads and disc-earning